Success Commercial but a little weak in R&D - Recensione dipendente - Principal Statistician presso AstraZeneca

3,0
12 nov 2024
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

strong pipelines, good future, and successful commercial launch across the world

Svantaggi

not an R&D driven company so statisticians or other functions in development do not have a very good chance to stand out.

Esplora altre recensioni su AstraZeneca

5,0
25 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Good products, great oncology pipeline

Svantaggi

Global leaders moving to US that have limited understanding of US environment

4,0
29 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Lots to learn with multiple launches and focus on AI

Svantaggi

heavy middle layer slows down decision making

Vedi recensioni per: Utile|Valutazione|Data|Tutto